A health technology assessment of the new drugs for inoperable or metastatic malignant melanoma patients
Pike E, Torkilseng EB, Sæterdal I, Jimenez E, Odgaard-Jensen J, Harboe I, Klemp M
Record ID 32015001239
English
Authors' recommendations:
We assessed the effectiveness and cost-effectiveness of seven new drugs used for inoperable or metastatic malignant melanoma patients relative to each other in the Norwegian setting.
None of the interventions are cost-effective at the maximum pharmacy retail prices, and the budget impact if the interventions are accepted in clinical practice are substantial. Drug price reductions in the region of 63 to 84 percent would be necessary to improve the cost-effectiveness and reduce the budget impact.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.kunnskapssenteret.no/en/publications/A+health+technology+assessment+of+the+new+drugs+for+inoperable+or+metastatic+malignant+melanoma+patients
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Norway
MeSH Terms
- Humans
- Melanoma
- Skin Neoplasms
- Technology Assessment, Biomedical
- Drug Therapy
Contact
Organisation Name:
Norwegian Institute of Public Health
Contact Address:
Universitetsgata 2, Postbox 7004 St. Olavs plass, NO-0310 Oslo NORWAY. Tel: +47 23 25 50 00; Fax: +47 23 25 50 10;
Contact Name:
Berit.Morland@nokc.no, dagny.fredheim@nokc.no
Contact Email:
Berit.Morland@nokc.no, dagny.fredheim@nokc.no
Copyright:
Norwegian Knowledge Centre for the Health Services (NOKC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.